MEREO BIOPHARMA GROUP PLC Accrued Professional Fees
MEREO BIOPHARMA GROUP PLC (MREO) had Accrued Professional Fees of $108.00 thousand as of 2025-03-31, per its 10-Q filed 2025-05-13.
Financial Statements › Notes › Payables and Accruals › Accrued Liabilities
us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent · last filed 2025-05-13
- 2025-03-31: Accrued Professional Fees $108.00K.
- 2024-12-31: Accrued Professional Fees $158.00K.
- 2024-09-30: Accrued Professional Fees $145.00K.
- 2024-06-30: Accrued Professional Fees $223.00K.
| Period end | Accrued Professional Fees |
|---|---|
| 2025-03-31 | $108.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $158.00K 10-Q · filed 2025-05-13 |
| 2024-09-30 | $145.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $223.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $353.00K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $338.00K 10-K · filed 2025-03-26 |
| 2022-12-31 | $183.00K 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |